Date: 04 December 2017
Macclesfield District General Hospital is leading the way nationally with the highest number of patients recruited to a menopause research study.
Up to September 2017, the team had recruited 24 participants to FOAM – a trial assessing the effectiveness of folic acid in reducing the number and severity of hot flushes in post-menopausal women.
This made Macclesfield, part of East Cheshire NHS Trust, the highest recruiting site of the nine participating centres across the country.
In fact, the team has been the highest recruiter in the country since September 2016. City Hospital, Birmingham, and Royal Shrewsbury Hospital are the next best with 18 recruitments.
The Phase III randomised study is on the National Institute for Health Research portfolio.
It is being run by the Cancer Research UK Clinical Trials Unit at the University of Birmingham.
Dalbir Kaur, FOAM Trial Coordinator, said: “The staff efforts at Macclesfield District General Hospital have been greatly appreciated and all their hard work is evident in their positive recruitment figures for the FOAM trial.
“With such great staff, I have no doubt that these efforts will continue and see us through to our overall target of 162 patients.”
The trial is designed for women who have had breast cancer, or endometrial cancer which affects the womb.
Women who do not have cancer but have entered the menopause can also qualify.
Participants must be aged between 40 and 70 and suffer 50 or more hot flushes a week.
Suitable participants are randomly allocated to receive either a folic acid tablet or a placebo “dummy drug” tablet once a day for 12 weeks.
During the course of the trial, they must make six hospital visits, complete four questionnaires, asking about other menopausal symptoms, and provide blood and urine samples.
Barbara Townley, Senior Oncology Research Sister at Macclesfield, said: “The team here are doing a fantastic job in recruiting patients to the FOAM study and our position at the top of the national table, ahead of the Chief Investigator site, is testament to all the hard work from everyone involved across the trust.
“New and effective treatment is needed to control menopausal symptoms and we are proud to be playing a leading role in a research study which could make the experience much more comfortable for women everywhere.”
The national target for FOAM is 162 patients by 4 May 2018, with 87 having been recruited as of September.
You may also be interested in